aTyr Pharma Announces Alignment with FDA on Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis

Stock Information for aTyr Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About aTyr Pharma Inc.

aTyr Pharma Announces Research Collaboration with Montefiore Einstein
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma Announces Second Quarter 2026 Results, Program Prioritization and Corporate Restructuring to Support Efzofitimod Program in ILD
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT(TM) Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing
Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.